Sezer, A. Et Al. 2021. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. LANCET , vol.397, no.10274 , 592-604.

Sezer, A., Kılıçkap, S., Gümüş, M., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., ... Türk, H. M.(2021). Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. LANCET , vol.397, no.10274, 592-604.

Sezer, Ahmet Et Al. "Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial," LANCET , vol.397, no.10274, 592-604, 2021

Sezer, Ahmet Et Al. "Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial." LANCET , vol.397, no.10274, pp.592-604, 2021

Sezer, A. Et Al. (2021) . "Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial." LANCET , vol.397, no.10274, pp.592-604.

@article{article, author={Ahmet Sezer Et Al. }, title={Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial}, journal={LANCET}, year=2021, pages={592-604} }